Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health has signed a definitive agreement for a $5 million non-dilutive royalty financing transaction, related to future sales of crofelemer (Mytesi) for a COVID-related indication targeting long-hauler patients. This financing will support regulatory activities and the development pipeline for crofelemer. The company is also identifying key opinion leaders in the US and Europe to address symptoms affecting COVID-19 survivors. With no royalty payments due for 36 months, Jaguar aims to leverage this opportunity to explore the growing market of long-hauler syndrome.
Jaguar Health has signed a binding agreement for a $5 million non-dilutive royalty financing to support the development of crofelemer for a COVID-related indication in long-hauler patients. This financing adds to previous transactions totaling $12 million since late 2020. The company aims for accelerated conditional approval of crofelemer in the EU. The Dragon SPAC, targeting AIM Italia, will focus on Napo EU's projects, providing additional updates expected next week. Mytesi, approved by the FDA, serves as an anti-diarrheal for adults with HIV/AIDS.
Jaguar Health has launched the Napo EU website in Italy, providing resources on post-COVID-19 long-hauler syndrome, including gastrointestinal symptoms like diarrhea. The site links to relevant studies and aims to explore the conditional marketing authorization of crofelemer for inflammatory diarrhea in long-hauler patients in Europe. In a recent study, 30% of COVID-19 survivors reported ongoing symptoms, highlighting the potential market for Jaguar's Mytesi product. The company continues to advocate for its plant-based therapies targeting GI distress.
Jaguar Health (NASDAQ:JAGX) is advancing plans for an exclusive relationship with the Dragon SPAC, targeting the listing of its subsidiary, Napo EU, on AIM Italia. An MOU has been signed with Josh Mailman, the lead sponsor of Dragon SPAC, which will negotiate the merger with Napo EU. The company is also seeking conditional marketing authorization in Europe for crofelemer to treat inflammatory diarrhea, particularly among 'long-hauler' COVID-19 patients. A meeting with European regulatory authorities is scheduled for March 2021.
Jaguar Health (NASDAQ:JAGX) announced a Memorandum of Understanding (MOU) with the Dragon SPAC to enable Napo EU’s anticipated listing on AIM Italia. The focus is on seeking conditional marketing authorization for crofelemer to treat inflammatory diarrhea in long-hauler COVID-19 patients in Europe. The partnership aims to leverage Napo's experience in developing plant-based drugs, particularly crofelemer, which is currently used for noninfectious diarrhea in HIV/AIDS patients. The potential market includes 20-70 million people in Europe suffering from gastrointestinal issues related to long COVID.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast on January 27, 2021, at 8:30 AM ET to discuss updates on the proposed merger of its anticipated subsidiary Napo EU with a special purpose acquisition company (SPAC) focused on Post Pandemic Recovery. Jaguar is exploring conditional marketing authorization in Europe for crofelemer, aimed at addressing gastrointestinal issues in long-hauler COVID-19 patients. The webcast will feature CEO Lisa Conte and Andreea Porcelli as co-presenters.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the granting of nonstatutory stock options to new employees as inducement awards. Effective December 9, 2020, one employee received options for 1,500 shares, while another received options for 35,000 shares, with an exercise price of $0.353. Additionally, on January 7, 2021, another employee was granted options for 7,000 shares at $2.68 per share. All options vest over three years, subject to continued employment. These options are part of the Company's strategy to attract and retain talent.
Jaguar Health, Inc. (NASDAQ:JAGX) announced on January 21, 2021, that it has regained compliance with Nasdaq's bid price requirement, as stated by the Nasdaq Hearings Panel on October 28, 2020. CEO Lisa Conte expressed satisfaction with this achievement, attributing it to the company's efforts since Q2 2020, such as expanding patient access to Mytesi® and securing a $6 million royalty-based capital infusion. The company is also advancing a Phase 3 clinical trial for crofelemer aimed at treating cancer therapy-related diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast on January 27, 2021, at 8:30 AM ET regarding its potential merger with Post Pandemic Recovery Equity SPAC. Lisa Conte, CEO of Jaguar, and Andreea Porcelli, SPAC sponsor and CEO of Swiss Growth Forum, will co-present updates. The company aims to explore conditional marketing authorization in Europe for its product addressing gastrointestinal distress related to long COVID. Mytesi, Jaguar's FDA-approved medication, is positioned to aid patients suffering from ongoing symptoms post-COVID-19.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the successful issuance of a $6 million secured promissory note to Streeterville Capital, LLC. The financing supports the development of lechlemer, aimed at treating diarrhea and dehydration in cholera patients. The investor holds a right to 18% of gross proceeds from a potential tropical disease priority review voucher (TDPRV). This program incentivizes drug development for neglected diseases and has seen previous vouchers sold for up to $350 million. Napo Pharmaceuticals, Jaguar's subsidiary, is conducting ongoing preclinical studies for lechlemer, which is derived from the Croton lechleri tree.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
